The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform

John L D Atkinson - One of the best experts on this subject based on the ideXlab platform.

  • Thyroid Stimulating Hormone pituitary adenomas
    Journal of Neurosurgery, 2008
    Co-Authors: Michelle J Clarke, Dana Erickson, Regina M Castro, John L D Atkinson
    Abstract:

    Object Thyroid-Stimulating Hormone (TSH)–secreting pituitary adenomas are rare, representing < 2% of all pituitary adenomas. Methods The authors conducted a retrospective analysis of patients with TSH-secreting or clinically silent TSH-immunostaining pituitary tumors among all pituitary adenomas followed at their institution between 1987 and 2003. Patient records, including clinical, imaging, and pathological and surgical characteristics were reviewed. Twenty-one patients (6 women and 15 men; mean age 46 years, range 26–73 years) were identified. Of these, 10 patients had a history of clinical hyperThyroidism, of whom 7 had undergone ablative Thyroid procedures (Thyroid surgery/131I ablation) prior to the diagnosis of pituitary adenoma. Ten patients had elevated TSH preoperatively. Seven patients presented with headache, and 8 presented with visual field defects. All patients underwent imaging, of which 19 were available for imaging review. Sixteen patients had macroadenomas. Results Of the 21 patients, 1...

Terry F. Davies - One of the best experts on this subject based on the ideXlab platform.

  • The Influence of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on Osteoclastogenesis
    Thyroid : official journal of the American Thyroid Association, 2011
    Co-Authors: Syed A. Morshed, Rauf Latif, Mone Zaidi, Terry F. Davies
    Abstract:

    Background: We have shown that Thyroid-Stimulating Hormone (TSH) has a direct inhibitory effect on osteoclastic bone resorption and that TSH receptor (TSHR) null mice display osteoporosis. To determine the stage of osteoclast development at which TSH may exert its effect, we examined the influence of TSH and agonist TSHR antibodies (TSHR-Ab) on osteoclast differentiation from murine embryonic stem (ES) cells to gain insight into bone remodeling in hyperThyroid Graves' disease. Methods: Osteoclast differentiation was initiated in murine ES cell cultures through exposure to macrophage colony stimulation factor, receptor activator of nuclear factor кB ligand, vitamin D, and dexamethasone. Results: Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts formed in ∼12 days. This coincided with the expected downregulation of known markers of self renewal and pluripotency (including Oct4, Sox2, and REX1). Both TSH and TSHR-Abs inhibited osteoclastogenesis as evidenced by decreased development of TRAP-pos...

  • The Genetics of the Thyroid Stimulating Hormone Receptor: History and Relevance
    Thyroid : official journal of the American Thyroid Association, 2010
    Co-Authors: Terry F. Davies, Xiaoming Yin, Rauf Latif
    Abstract:

    Background: The Thyroid Stimulating Hormone receptor (TSHR) is the key regulator of thyrocyte function. The gene for the TSHR on chromosome 14q31 has been implicated as coding for the major autoant...

  • The Thyroid-Stimulating Hormone receptor: impact of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone receptor antibodies on multimerization, cleavage, and signaling.
    Endocrinology and metabolism clinics of North America, 2009
    Co-Authors: Rauf Latif, Syed A. Morshed, Mone Zaidi, Terry F. Davies
    Abstract:

    The Thyroid-Stimulating Hormone receptor (TSHR) has a central role in thyrocyte function and is also one of the major autoantigens for the autoimmune Thyroid diseases. We review the post-translational processing, multimerization, and intramolecular cleavage of TSHR, all of which may modulate its signal transduction. The recent characterization of monoclonal antibodies to the TSHR, including Stimulating, blocking, and neutral antibodies, have also revealed unique biologic insights into receptor activation and the variety of these TSHR antibodies may help explain the multiple clinical phenotypes seen in autoimmune Thyroid diseases. Knowledge of the structure/function relationship of the TSHR is beginning to provide a greater understanding of Thyroid physiology and Thyroid autoimmunity.

Ruth M Ayling - One of the best experts on this subject based on the ideXlab platform.

  • an immunoglobulin g complexed form of Thyroid Stimulating Hormone macro Thyroid Stimulating Hormone is a cause of elevated serum Thyroid Stimulating Hormone concentration
    Annals of Clinical Biochemistry, 2013
    Co-Authors: Francesca Mills, Jinny Jeffery, Paul Mackenzie, Alex Cranfield, Ruth M Ayling
    Abstract:

    BackgroundMacrocomplexes can be the cause of elevated serum Hormone concentrations and may cause diagnostic confusion. This is well recognized for prolactin and commonly screened for using polyethylene glycol (PEG) precipitation. The phenomenon and a suitable screening method is less familiar with respect to Thyroid-Stimulating Hormone (TSH).MethodSamples sent to the laboratory for routine analysis of Thyroid function and found to have a TSH >10 mU/L were evaluated to determine the prevalence of macro-TSH in the Roche Elecsys assay, using PEG precipitation with confirmation by gel filtration chromatography.ResultsOf 495 samples tested, 3 (0.6%) were found to have macro-TSH. From the distribution of recoveries, a cut-off <25% was determined for identifying samples requiring further investigation for the presence of macro-TSH.ConclusionThe prevalence of elevated TSH due to macro-TSH was found to be 0.6%. Laboratories should be aware of this cause of assay interference.

  • An immunoglobulin G complexed form of Thyroid-Stimulating Hormone (macro Thyroid-Stimulating Hormone) is a cause of elevated serum Thyroid-Stimulating Hormone concentration
    Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine, 2013
    Co-Authors: Francesca Mills, Jinny Jeffery, Paul Mackenzie, Alex Cranfield, Ruth M Ayling
    Abstract:

    BackgroundMacrocomplexes can be the cause of elevated serum Hormone concentrations and may cause diagnostic confusion. This is well recognized for prolactin and commonly screened for using polyethylene glycol (PEG) precipitation. The phenomenon and a suitable screening method is less familiar with respect to Thyroid-Stimulating Hormone (TSH).MethodSamples sent to the laboratory for routine analysis of Thyroid function and found to have a TSH >10 mU/L were evaluated to determine the prevalence of macro-TSH in the Roche Elecsys assay, using PEG precipitation with confirmation by gel filtration chromatography.ResultsOf 495 samples tested, 3 (0.6%) were found to have macro-TSH. From the distribution of recoveries, a cut-off

Rauf Latif - One of the best experts on this subject based on the ideXlab platform.

  • The Influence of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on Osteoclastogenesis
    Thyroid : official journal of the American Thyroid Association, 2011
    Co-Authors: Syed A. Morshed, Rauf Latif, Mone Zaidi, Terry F. Davies
    Abstract:

    Background: We have shown that Thyroid-Stimulating Hormone (TSH) has a direct inhibitory effect on osteoclastic bone resorption and that TSH receptor (TSHR) null mice display osteoporosis. To determine the stage of osteoclast development at which TSH may exert its effect, we examined the influence of TSH and agonist TSHR antibodies (TSHR-Ab) on osteoclast differentiation from murine embryonic stem (ES) cells to gain insight into bone remodeling in hyperThyroid Graves' disease. Methods: Osteoclast differentiation was initiated in murine ES cell cultures through exposure to macrophage colony stimulation factor, receptor activator of nuclear factor кB ligand, vitamin D, and dexamethasone. Results: Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts formed in ∼12 days. This coincided with the expected downregulation of known markers of self renewal and pluripotency (including Oct4, Sox2, and REX1). Both TSH and TSHR-Abs inhibited osteoclastogenesis as evidenced by decreased development of TRAP-pos...

  • The Genetics of the Thyroid Stimulating Hormone Receptor: History and Relevance
    Thyroid : official journal of the American Thyroid Association, 2010
    Co-Authors: Terry F. Davies, Xiaoming Yin, Rauf Latif
    Abstract:

    Background: The Thyroid Stimulating Hormone receptor (TSHR) is the key regulator of thyrocyte function. The gene for the TSHR on chromosome 14q31 has been implicated as coding for the major autoant...

  • The Thyroid-Stimulating Hormone receptor: impact of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone receptor antibodies on multimerization, cleavage, and signaling.
    Endocrinology and metabolism clinics of North America, 2009
    Co-Authors: Rauf Latif, Syed A. Morshed, Mone Zaidi, Terry F. Davies
    Abstract:

    The Thyroid-Stimulating Hormone receptor (TSHR) has a central role in thyrocyte function and is also one of the major autoantigens for the autoimmune Thyroid diseases. We review the post-translational processing, multimerization, and intramolecular cleavage of TSHR, all of which may modulate its signal transduction. The recent characterization of monoclonal antibodies to the TSHR, including Stimulating, blocking, and neutral antibodies, have also revealed unique biologic insights into receptor activation and the variety of these TSHR antibodies may help explain the multiple clinical phenotypes seen in autoimmune Thyroid diseases. Knowledge of the structure/function relationship of the TSHR is beginning to provide a greater understanding of Thyroid physiology and Thyroid autoimmunity.

Michelle J Clarke - One of the best experts on this subject based on the ideXlab platform.

  • Thyroid Stimulating Hormone pituitary adenomas
    Journal of Neurosurgery, 2008
    Co-Authors: Michelle J Clarke, Dana Erickson, Regina M Castro, John L D Atkinson
    Abstract:

    Object Thyroid-Stimulating Hormone (TSH)–secreting pituitary adenomas are rare, representing < 2% of all pituitary adenomas. Methods The authors conducted a retrospective analysis of patients with TSH-secreting or clinically silent TSH-immunostaining pituitary tumors among all pituitary adenomas followed at their institution between 1987 and 2003. Patient records, including clinical, imaging, and pathological and surgical characteristics were reviewed. Twenty-one patients (6 women and 15 men; mean age 46 years, range 26–73 years) were identified. Of these, 10 patients had a history of clinical hyperThyroidism, of whom 7 had undergone ablative Thyroid procedures (Thyroid surgery/131I ablation) prior to the diagnosis of pituitary adenoma. Ten patients had elevated TSH preoperatively. Seven patients presented with headache, and 8 presented with visual field defects. All patients underwent imaging, of which 19 were available for imaging review. Sixteen patients had macroadenomas. Results Of the 21 patients, 1...